GleamWall
中文EN

MDCX Medicus Pharma Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1997296 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY160.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-415.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets172.2%
Debt / equity—
Current ratio0.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-101.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.72M$3.53M
SG&A expense$17.92M$7.65M
Operating income-$34.36M-$11.18M
Pretax income-$16.82M-$6.19M
Income tax$0$0
Net income-$47.28M-$11.16M
EPS (basic)-2.74-1.16
EPS (diluted)-2.74-1.16
Weighted avg. shares (diluted)17.28M9.62M
Banking
Net interest income-$197,382$25,386
Balance sheet
Cash & equivalents$8.71M$4.16M
Current assets$9.89M$5.38M
Total assets$10.06M$5.65M
Current liabilities$9.94M$2.31M
Short-term debt$5.25M$0
Total liabilities$10.02M$2.51M
Shareholders' equity-$67,554$3.13M
Shares outstanding503,52611.82M
Cash flow statement
Operating cash flow-$22.78M-$10.25M
Investing cash flow-$4.62M$0
Financing cash flow$31.94M$12.69M
Stock-based compensation$1.51M$713,119

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.